News

The severity of seizures was reduced among Dravet syndrome patients in the U.K. over 10 years, but developmental outcomes worsened, a recent analysis shows. Children younger than age 6 generally tended to see a worse trajectory during that period than older patients, including having a higher burden of coexisting…

Avicanna has launched a new version of its proprietary oral cannabidiol (CBD) formulation, called RHO Phyto Micro Drop 10, in Canada. The new product will be available to certain Canadian patients, including individuals with seizures, who have medical authorization through a medical cannabis care platform, according to a…

Treatment with the investigational therapy STK-001 led to significant reductions in seizure frequency and clinically meaningful improvements in cognition and behavior for children and adolescents with Dravet syndrome, according to data from Phase 1/2 studies and their open-label extensions (OLEs). Developer Stoke Therapeutics said that the findings…

Recurrent seizures in a man with Dravet syndrome and high body temperature were managed by treating the recurrent infections and switching from Zonegran (zonisamide) to Fycompa (perampanel), a case study reports. The researchers recommended that clinicians consider treating infections early and discontinuing Zonegra if the medication causes…

Fycompa (perampanel) was found to safely reduce seizure frequency among patients with genetic forms of epilepsy, including Dravet syndrome, in a recent analysis of real-world treatment data. Findings from the analysis of pooled clinical practice data showed treatment responses among these genetic epilepsy patients were at least as…

Levodopa, the standard treatment for motor symptoms associated with Parkinson’s disease, improved walking abilities in people with Dravet syndrome, according to a small clinical trial. Most walking gains occurred in younger patients with better walking abilities before levodopa treatment. “Our findings suggest that levodopa treatment may be…

A molecule designed to enhance activity at certain GABA-A receptor proteins in the brain protected against seizures and eased anxiety in a mouse model of Dravet syndrome, recent research showed. At higher doses, the medication led to sedative side effects, which scientists believe can be avoided by making sure…

Behavioral development in children and teens with Dravet syndrome generally held stable in the first year of an observational study, though some showed small improvements in communication, according to researchers. Participants in the study, dubbed BUTTERFLY, continued to perform below what would be expected of their typically developing peers…

Encoded Therapeutics has been cleared by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to begin clinical testing of ETX101, an investigational one-time gene therapy for children with Dravet syndrome. A Phase 1/2 clinical study dubbed EXPEDITION will test how safe ETX101 is and how well it…

The National Institute of Drug and Food Surveillance (INVIMA) of Colombia has approved Trunerox as an add-on treatment for seizures in people with Dravet syndrome and Lennox-Gastaut syndrome (LGS). Trunerox, which was developed by the Canadian biopharmaceutical Avicanna, is a proprietary oral formulation of 10% cannabidiol…